Amy Schulman - May 29, 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Director
Signature
By: Brett Budzinski, Attorney-in-Fact For: Amy Schulman
Stock symbol
ALNY
Transactions as of
May 29, 2024
Transactions value $
-$1,219,646
Form type
4
Date filed
5/31/2024, 07:00 PM
Previous filing
May 20, 2024
Next filing
Jun 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $2M +30K +22058.82% $66.83 30.1K May 29, 2024 Direct F1
transaction ALNY Common Stock Sale -$1.5M -10.1K -33.58% $148.21 20K May 29, 2024 Direct F1, F2
transaction ALNY Common Stock Sale -$1.72M -11.5K -57.54% $148.93 8.5K May 29, 2024 Direct F1, F3
transaction ALNY Common Stock Sale -$9.43K -63 -0.74% $149.76 8.44K May 29, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Options Exercise $0 -30K -100% $0.00* 0 May 29, 2024 Common Stock 30K $66.83 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.62 to $148.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.63 to $149.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 This stock option was fully vested and exercisable as of July 1, 2017.